Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Sano Genetics. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sano Genetics or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

EP 215: Vectorized RNAi and the next frontier of gene silencing with Rachel Salzman of Armatus Bio

43:33
 
Share
 

Manage episode 521473481 series 2631947
Content provided by Sano Genetics. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sano Genetics or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Summary:

This week on The Genetics Podcast, Patrick is joined by Dr. Rachel Salzman, CEO of Armatus Bio. They discuss the promise of vectorized RNAi for autosomal dominant diseases, the key scientific and clinical hurdles in gene therapy, and Rachel’s lessons from two decades in the field.

Show Notes:

0:00 Intro to The Genetics Podcast

01:00 Welcome to Rachel

01:35 Background of Armatus Bio and the mechanism behind its vectorized RNAi platform

05:31 Advantages of vectorized RNAi over conventional RNAi approaches

08:07 How microRNAs work and how engineered versions enable highly specific gene silencing

10:28 Current preclinical progress at Armatus and next steps toward first-in-human trials

14:06 Lessons on making smart risk decisions in rare disease drug development

17:26 Reflections on two decades of progress, setbacks, and realities in gene therapy

22:07 Hemophilia as a case study in gene therapy missteps and overlooked patient and market realities

25:21 Challenges around product purity and the need for financial innovation

29:23 Why AAV purity is so difficult to achieve and where pre-competitive collaboration could drive improvement

33:32 Rachel’s path from veterinary medicine to gene therapy through a family genetic diagnosis

35:58 Founding the Stop ALD Foundation and advancing lentiviral gene therapy into first-in-human use

39:58 The future potential of vectorized RNAi

42:00 Closing remarks

Please consider rating and reviewing us on your chosen podcast listening platform!

https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

  continue reading

218 episodes

Artwork
iconShare
 
Manage episode 521473481 series 2631947
Content provided by Sano Genetics. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sano Genetics or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Summary:

This week on The Genetics Podcast, Patrick is joined by Dr. Rachel Salzman, CEO of Armatus Bio. They discuss the promise of vectorized RNAi for autosomal dominant diseases, the key scientific and clinical hurdles in gene therapy, and Rachel’s lessons from two decades in the field.

Show Notes:

0:00 Intro to The Genetics Podcast

01:00 Welcome to Rachel

01:35 Background of Armatus Bio and the mechanism behind its vectorized RNAi platform

05:31 Advantages of vectorized RNAi over conventional RNAi approaches

08:07 How microRNAs work and how engineered versions enable highly specific gene silencing

10:28 Current preclinical progress at Armatus and next steps toward first-in-human trials

14:06 Lessons on making smart risk decisions in rare disease drug development

17:26 Reflections on two decades of progress, setbacks, and realities in gene therapy

22:07 Hemophilia as a case study in gene therapy missteps and overlooked patient and market realities

25:21 Challenges around product purity and the need for financial innovation

29:23 Why AAV purity is so difficult to achieve and where pre-competitive collaboration could drive improvement

33:32 Rachel’s path from veterinary medicine to gene therapy through a family genetic diagnosis

35:58 Founding the Stop ALD Foundation and advancing lentiviral gene therapy into first-in-human use

39:58 The future potential of vectorized RNAi

42:00 Closing remarks

Please consider rating and reviewing us on your chosen podcast listening platform!

https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

  continue reading

218 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play